Gut microbiome disparities reflect type-2 diabetes progression and medication status
Gut microbiome profiles of 95 subjects, including individuals with diagnosed T2D (KT2D, n=40), undiagnosed T2D (UT2D, n=15), pre-diabetes (PD, n=25), and healthy control counterparts (Ctrl, n=15) were analyzed using high-throughput, full-length 16S (V1-V9) long-read sequencing using the PacBio-Sequel-II platform.